Option chain shows key data for China SXT Pharmaceuticals's stock options at various strike prices and expiration dates. Traders use this information to analyze potential trades and assess market sentiment for China SXT Pharmaceuticals.

China SXT Pharmaceuticals (NASDAQ:SXTC) Stock, Option Chain

China SXT Pharmaceuticals Inc is a pharmaceutical company that is focused on the research, development, manufacture, marketing, and sales of Traditional Chinese Medicine Pieces (TCMP), particularly, TCMP (Directed-oral TCMP, and After-soaking TCMP) which is a sort of Traditional Chinese Medicine (TCM) that has been processed to be ready for use without decoction. Geographically, the firm generates its revenue from the People's Republic of China.

Intel, Cleanspark, Super Micro Computer, Upstart, Tesla: Why These 5 Stocks Are On Investors' Radars Today

News

Pre-Market Outlook

Markets

Movers

Trading Ideas

ALBT

AUMN

BIOA

ESSA

GXAI

HCTI

ORIS

RENT

RIME

SATL

SBET

SPCB

SXTC

ZBAO

Why Interpublic Shares Are Trading Higher By Around 14%; Here Are 20 Stocks Moving Premarket

movers image

AILE

ALTM

BKYI

CNEY

FTCI

MPLN

PLAY

RLAY

SLXN

TANH

TBIO

TOMZ

Why Dave &amp; Buster&#39;s Shares Are Trading Higher By Around 13%; Here Are 20 Stocks Moving Premarket

Intraday Update

ACHR

AGRI

ASPI

BDRX

BILI

CGBS

COCO

ERIC

EVGO

EYPT

FWRD

HOVR

IMMP

KZIA

LCFY

LCID

LIPO

NISN

PEGY

Qualigen Therapeutics, Inc. - Common Stock

QLGN

RNLX

SANW

SISI

SNTG

TOYO

VALU

VRPX

VSTM

YGMZ

ZAPP

Why ASP Isotopes Shares Are Trading Lower By 9%? Here Are Other Stocks Moving In Friday&#39;s Mid-Day Session

China SXT Pharmaceuticals, Inc. - Common Stock

China SXT Pharmaceuticals Inc

<p>Intel Corp. has shortlisted a number of buyout firms for the next round of bidding for its Altera unit, according to people familiar with the matter, as the beleaguered chipmaker makes headway on a process started by its now ousted chief executive officer.&nbsp;</p>
<p><a href="https://www.bloomberg.com/news/articles/2024-12-19/intel-shortlists-suitors-for-programmable-chip-arm-altera?utm_source=google&amp;utm_medium=bd&amp;cmpId=google" title="https://www.bloomberg.com/news/articles/2024-12-19/intel-shortlists-suitors-for-programmable-chip-arm-altera?utm_source=google&amp;utm_medium=bd&amp;cmpId=google">https://www.bloomberg.com/news/articles/2024-12-19/intel-shortlists-suitors-for-programmable-chip-arm-altera?utm_source=google&amp;utm_medium=bd&amp;cmpId=google</a></p>


Asset Sales

INTC

'Intel Shortlists Suitors for Programmable Chip Arm Altera' - Bloomberg

<p><strong>Trump Media &amp; Technology Group Corp</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DJT#NASDAQ">DJT</a>) is drawing attention as its technical setup hints at a <a href="https://www.benzinga.com/topic/golden-cross">potential <strong>Golden Cross</strong></a> <em>—</em> a bullish signal that could spark investor excitement.</p>
<p>Yet, the road ahead for DJT stock isn't without twists, much like the unconventional journey of its parent company.</p>
<h2 class="wp-block-heading">Golden Cross In Sight For DJT Stock?</h2>
<p><figure class="wp-block-image size-full"><a href="https://bzresearch.myclickfunnels.com/benzinga-pro-content-webinar-registration/?utm_source=BZprocontent121924&amp;t=be2bearmibe3na1"><img loading="lazy" decoding="async" width="630" height="493" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/12/19125622/Screenshot-2024-12-19-at-8.05.57-PM.png" alt="" class="wp-image-700348" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2024/12/19125622/Screenshot-2024-12-19-at-8.05.57-PM.png 630w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/12/19125622/Screenshot-2024-12-19-at-8.05.57-PM-300x235.png 300w" sizes="(max-width: 630px) 100vw, 630px" /></a></figure></p>
<p><a href="https://bzresearch.myclickfunnels.com/benzinga-pro-content-webinar-registration/?utm_source=BZprocontent121924&amp;t=be2bearmibe3na1"><em>Chart created using Benzinga Pro</em></a></p>
<p>DJT stock's 200-day simple moving average (SMA) sits at $33.49, while its 50-day SMA has climbed to $33.26. With DJT trading at $36.25, the 50-day SMA could soon overtake the 200-day SMA—a textbook golden cross. Historically, this signal often heralds a strong upward trend.</p>
<p>But not so fast—short-term indicators tell a more complex story. The stock's eight-day SMA of $36.41 almost coincides with the current price, implying near-term caution, while its moving average convergence/divergence (MACD) of 1.53 and relative strength index (RSI) of 55.87 suggest moderate bullish momentum. </p>
<p>Add in selling pressure, and you have a stock with mixed signals that might leave investors scratching their heads.</p>
<p><strong>Read Also: <a href="https://www.benzinga.com/24/12/42498758/truth-social-ceo-nunes-to-head-trumps-intelligence-advisory-board">Truth Social CEO Nunes to Head Trump&#8217;s Intelligence Advisory Board</a></strong></p>
<h2 class="wp-block-heading">Truth+ And The Trump Factor</h2>
<p>Behind DJT's market intrigue lies its parent company, Trump Media &amp; Technology Group, blend of media and politics. The company's streaming platform, Truth+, has expanded to include 18 channels offering conservative talk shows, live news, and weather programming.</p>
<p>With former political staffers turned hosts and a market cap of $7.6 billion, TMTG occupies a unique space where business meets politics. </p>
<p>President-elect <strong>Donald Trump</strong>, the majority shareholder, maintains no formal role at TMTG but benefits significantly from its success.</p>
<h2 class="wp-block-heading">Balancing Opportunity And Risk</h2>
<p>Investors eyeing DJT for its potential golden cross may also want to weigh the risks. The stock's recent 18.28% surge over the past month highlights strong momentum, but selling pressure could curb further gains.</p>
<p>In the end, DJT embodies the unpredictability of its namesake: bold, headline-grabbing, and anything but boring. Whether the golden cross materializes or fizzles, one thing's for sure—DJT stock is a story to watch.</p>
<p><strong>Read Next: </strong></p>
<ul>
<li><strong><a href="https://www.benzinga.com/markets/cryptocurrency/24/12/42571395/trumps-djt-connection-drives-this-lesser-known-crypto-stocks-nearly-3x-surge-in-a-month">Trump&#8217;s DJT Connection Drives This Lesser-Known Crypto Stock&#8217;s Nearly 3X Surge In A Month</a></strong></li>
</ul>
<p><em>Image: Shutterstock</em></p>


Social Media

Technicals

Tech

General

DJT Stock Eyes Golden Cross As Truth+ Expands Its Reach

<p>Whales with a lot of money to spend have taken a noticeably bearish stance on <strong>Intel</strong>.</p>
<p>Looking at options history for Intel (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INTC#NASDAQ">INTC</a>) we detected 31 trades.</p>
<p>If we consider the specifics of each trade, it is accurate to state that 38% of the investors opened trades with bullish expectations and 54% with bearish.</p>
<p>From the overall spotted trades, 17 are puts, for a total amount of $2,575,335 and 14, calls, for a total amount of $697,550.</p>
<h3>What's The Price Target?</h3>
<p>Based on the trading activity, it appears that the significant investors are aiming for a price territory stretching from $14.0 to $30.0 for Intel over the recent three months. </p>
<h3>Insights into Volume &amp; Open Interest</h3>
<p>In today's trading context, the average open interest for options of Intel stands at 17705.65, with a total volume reaching 73,527.00. The accompanying chart delineates the progression of both call and put option volume and open interest for high-value trades in Intel, situated within the strike price corridor from $14.0 to $30.0, throughout the last 30 days.</p>
<h3>Intel Option Volume And Open Interest Over Last 30 Days</h3>
<p><img src="https://www.benzinga.com/files/images/story/2024/1734634871_0.png" alt="Options Call Chart" /></p>
<h3>Biggest Options Spotted:</h3>
<p>
<table>
<thead>
<tr>
<th><strong>Symbol</strong></th>
<th><strong>PUT/CALL</strong></th>
<th><strong>Trade Type</strong></th>
<th><strong>Sentiment</strong></th>
<th><strong>Exp. Date</strong></th>
<th><strong>Ask</strong></th>
<th><strong>Bid</strong></th>
<th><strong>Price</strong></th>
<th><strong>Strike Price</strong></th>
<th><strong>Total Trade Price</strong></th>
<th><strong>Open Interest</strong></th>
<th><strong>Volume</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td>INTC</td>
<td>PUT</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>04/17/25</td>
<td>$4.8</td>
<td>$4.7</td>
<td>$4.71</td>
<td>$23.00</td>
<td>$471.0K</td>
<td>2.8K</td>
<td>9.8K</td>
</tr>
<tr>
<td>INTC</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>04/17/25</td>
<td>$4.75</td>
<td>$4.7</td>
<td>$4.7</td>
<td>$23.00</td>
<td>$465.3K</td>
<td>2.8K</td>
<td>4.9K</td>
</tr>
<tr>
<td>INTC</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>04/17/25</td>
<td>$4.8</td>
<td>$4.75</td>
<td>$4.75</td>
<td>$23.00</td>
<td>$452.2K</td>
<td>2.8K</td>
<td>6.4K</td>
</tr>
<tr>
<td>INTC</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>04/17/25</td>
<td>$7.1</td>
<td>$7.05</td>
<td>$7.1</td>
<td>$26.00</td>
<td>$212.2K</td>
<td>994</td>
<td>300</td>
</tr>
<tr>
<td>INTC</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>09/19/25</td>
<td>$6.95</td>
<td>$6.85</td>
<td>$6.95</td>
<td>$25.00</td>
<td>$207.8K</td>
<td>28.5K</td>
<td>300</td>
</tr>
</tbody>
</table>
</p>
<h3>About Intel</h3>
<p>Intel is a leading digital chipmaker, focused on the design and manufacturing of microprocessors for the global personal computer and data center markets. Intel pioneered the x86 architecture for microprocessors and was the prime proponent of Moore's law for advances in semiconductor manufacturing. Intel remains the market share leader in central processing units in both the PC and server end markets. Intel has also been expanding into new adjacencies, such as communications infrastructure, automotive, and the Internet of Things. Further, Intel expects to leverage its chip manufacturing capabilities into an outsourced foundry model where it constructs chips for others.</p>
<p>After a thorough review of the options trading surrounding Intel, we move to examine the company in more detail. This includes an assessment of its current market status and performance.</p>
<h3>Intel's Current Market Status</h3>
<ul>
<li>Trading volume stands at 37,848,879, with INTC's price down by -0.72%, positioned at $19.16.</li>
<li>RSI indicators show the stock to be may be oversold.</li>
<li>Earnings announcement expected in 35 days.</li>
</ul>
<h3>What Analysts Are Saying About Intel</h3>
<p>Over the past month, 1 industry analysts have shared their insights on this stock, proposing an average target price of $21.0.</p>
<p><strong>Unusual Options Activity Detected: Smart Money on the Move</strong></p>
<p>Benzinga Edge's Unusual Options board spots potential market movers before they happen. See what positions big money is taking on your favorite stocks. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=Be8be9arja3be22bz20&amp;utm_source=benzinga-insights"><strong>Click here for access</strong></a>.<br />
&#x2A; An analyst from B of A Securities has revised its rating downward to Underperform, adjusting the price target to $21. </p>
<p>Trading options involves greater risks but also offers the potential for higher profits. Savvy traders mitigate these risks through ongoing education, strategic trade adjustments, utilizing various indicators, and staying attuned to market dynamics. Keep up with the latest options trades for Intel with <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a> for real-time alerts.</p>


Options

What the Options Market Tells Us About Intel

<p>Whales with a lot of money to spend have taken a noticeably bullish stance on <strong>GE Aero</strong>.</p>
<p>Looking at options history for GE Aero (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GE#NYSE">GE</a>) we detected 12 trades.</p>
<p>If we consider the specifics of each trade, it is accurate to state that 75% of the investors opened trades with bullish expectations and 8% with bearish.</p>
<p>From the overall spotted trades, 3 are puts, for a total amount of $163,690 and 9, calls, for a total amount of $469,022.</p>
<h3>What's The Price Target?</h3>
<p>Based on the trading activity, it appears that the significant investors are aiming for a price territory stretching from $125.0 to $190.0 for GE Aero over the recent three months. </p>
<h3>Volume &amp; Open Interest Development</h3>
<p>Assessing the volume and open interest is a strategic step in options trading. These metrics shed light on the liquidity and investor interest in GE Aero's options at specified strike prices. The forthcoming data visualizes the fluctuation in volume and open interest for both calls and puts, linked to GE Aero's substantial trades, within a strike price spectrum from $125.0 to $190.0 over the preceding 30 days.</p>
<h3>GE Aero Option Activity Analysis: Last 30 Days</h3>
<p><img src="https://www.benzinga.com/files/images/story/2024/1734634866_0.png" alt="Options Call Chart" /></p>
<h3>Noteworthy Options Activity:</h3>
<p>
<table>
<thead>
<tr>
<th><strong>Symbol</strong></th>
<th><strong>PUT/CALL</strong></th>
<th><strong>Trade Type</strong></th>
<th><strong>Sentiment</strong></th>
<th><strong>Exp. Date</strong></th>
<th><strong>Ask</strong></th>
<th><strong>Bid</strong></th>
<th><strong>Price</strong></th>
<th><strong>Strike Price</strong></th>
<th><strong>Total Trade Price</strong></th>
<th><strong>Open Interest</strong></th>
<th><strong>Volume</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td>GE</td>
<td>PUT</td>
<td>TRADE</td>
<td>NEUTRAL</td>
<td>12/27/24</td>
<td>$25.7</td>
<td>$25.15</td>
<td>$25.46</td>
<td>$190.00</td>
<td>$101.8K</td>
<td>50</td>
<td>50</td>
</tr>
<tr>
<td>GE</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>01/17/25</td>
<td>$1.0</td>
<td>$0.95</td>
<td>$1.0</td>
<td>$180.00</td>
<td>$100.1K</td>
<td>8.1K</td>
<td>4.8K</td>
</tr>
<tr>
<td>GE</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>01/17/25</td>
<td>$1.06</td>
<td>$1.0</td>
<td>$1.0</td>
<td>$180.00</td>
<td>$100.0K</td>
<td>8.1K</td>
<td>5.8K</td>
</tr>
<tr>
<td>GE</td>
<td>CALL</td>
<td>SWEEP</td>
<td>NEUTRAL</td>
<td>02/21/25</td>
<td>$41.0</td>
<td>$38.85</td>
<td>$39.93</td>
<td>$125.00</td>
<td>$59.8K</td>
<td>1</td>
<td>15</td>
</tr>
<tr>
<td>GE</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>01/17/25</td>
<td>$0.92</td>
<td>$0.9</td>
<td>$0.92</td>
<td>$180.00</td>
<td>$46.7K</td>
<td>8.1K</td>
<td>3.3K</td>
</tr>
</tbody>
</table>
</p>
<h3>About GE Aero</h3>
<p>GE Aerospace is the global leader in designing, manufacturing, and servicing large aircraft engines, along with partner Safran in their CFM joint venture. With its massive global installed base of nearly 70,000 commercial and military engines, GE Aerospace earns most of its profits on recurring service revenue of that equipment, which operates for decades. GE Aerospace is the remaining core business of the company formed in 1892 with historical ties to American inventor Thomas Edison; that company became a storied conglomerate with peak revenue of $130 billion in 2000. GE spun off its appliance, finance, healthcare, and wind and power businesses between 2016 and 2024.</p>
<p>After a thorough review of the options trading surrounding GE Aero, we move to examine the company in more detail. This includes an assessment of its current market status and performance.</p>
<h3>Present Market Standing of GE Aero</h3>
<ul>
<li>Currently trading with a volume of 2,554,093, the GE's price is up by 3.1%, now at $164.91. </li>
<li>RSI readings suggest the stock is currently may be approaching oversold.</li>
<li>Anticipated earnings release is in 33 days.</li>
</ul>
<h3>What The Experts Say On GE Aero</h3>
<p>A total of 1 professional analysts have given their take on this stock in the last 30 days, setting an average price target of $225.0.</p>
<p><strong>Unusual Options Activity Detected: Smart Money on the Move</strong></p>
<p>Benzinga Edge's Unusual Options board spots potential market movers before they happen. See what positions big money is taking on your favorite stocks. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=Be8be9arja3be22bz20&amp;utm_source=benzinga-insights"><strong>Click here for access</strong></a>.<br />
&#x2A; An analyst from Wells Fargo has decided to maintain their Overweight rating on GE Aero, which currently sits at a price target of $225. </p>
<p>Options trading presents higher risks and potential rewards. Astute traders manage these risks by continually educating themselves, adapting their strategies, monitoring multiple indicators, and keeping a close eye on market movements. Stay informed about the latest GE Aero options trades with real-time alerts from <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a>.</p>


What the Options Market Tells Us About GE Aero

<p>Celanese (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CE#NYSE">CE</a>) has been analyzed by 15 analysts in the last three months, revealing a diverse range of perspectives from bullish to bearish.</p>
<p>The table below summarizes their recent ratings, showcasing the evolving sentiments within the past 30 days and comparing them to the preceding months.</p>
<table>
<thead>
<tr>
<th></th>
<th align="right"><strong>Bullish</strong></th>
<th align="right"><strong>Somewhat Bullish</strong></th>
<th align="right"><strong>Indifferent</strong></th>
<th align="right"><strong>Somewhat Bearish</strong></th>
<th align="right"><strong>Bearish</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Total Ratings</strong></td>
<td align="right">1</td>
<td align="right">4</td>
<td align="right">7</td>
<td align="right">2</td>
<td align="right">1</td>
</tr>
<tr>
<td><strong>Last 30D</strong></td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>1M Ago</strong></td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>2M Ago</strong></td>
<td align="right">1</td>
<td align="right">2</td>
<td align="right">5</td>
<td align="right">2</td>
<td align="right">1</td>
</tr>
<tr>
<td><strong>3M Ago</strong></td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
<p>Insights from analysts' 12-month price targets are revealed, presenting an average target of $106.07, a high estimate of $163.00, and a low estimate of $73.00. Highlighting a 24.81% decrease, the current average has fallen from the previous average price target of $141.07. </p>
<p><img src="https://www.benzinga.com/files/images/story/2024/1734634861_0.png" alt="price target chart" /></p>
<h2>Analyzing Analyst Ratings: A Detailed Breakdown</h2>
<p>A comprehensive examination of how financial experts perceive Celanese is derived from recent analyst actions. The following is a detailed summary of key analysts, their recent evaluations, and adjustments to ratings and price targets.</p>
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Arun Viswanathan</td>
<td>RBC Capital</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$88.00</td>
<td>$122.00</td>
</tr>
<tr>
<td>Patrick Cunningham</td>
<td>Citigroup</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$73.00</td>
<td>$100.00</td>
</tr>
<tr>
<td>Michael Leithead</td>
<td>Barclays</td>
<td>Lowers</td>
<td>Equal-Weight</td>
<td>$88.00</td>
<td>$101.00</td>
</tr>
<tr>
<td>Joshua Spector</td>
<td>UBS</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$97.00</td>
<td>$161.00</td>
</tr>
<tr>
<td>John McNulty</td>
<td>BMO Capital</td>
<td>Lowers</td>
<td>Underperform</td>
<td>$76.00</td>
<td>$138.00</td>
</tr>
<tr>
<td>Charles Neivert</td>
<td>Piper Sandler</td>
<td>Lowers</td>
<td>Underweight</td>
<td>$98.00</td>
<td>$150.00</td>
</tr>
<tr>
<td>Arun Viswanathan</td>
<td>RBC Capital</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$122.00</td>
<td>$163.00</td>
</tr>
<tr>
<td>Michael Leithead</td>
<td>Barclays</td>
<td>Lowers</td>
<td>Equal-Weight</td>
<td>$101.00</td>
<td>$151.00</td>
</tr>
<tr>
<td>Ghansham Panjabi</td>
<td>Baird</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$110.00</td>
<td>$150.00</td>
</tr>
<tr>
<td>Vincent Andrews</td>
<td>Morgan Stanley</td>
<td>Lowers</td>
<td>Equal-Weight</td>
<td>$100.00</td>
<td>$140.00</td>
</tr>
<tr>
<td>David Begleiter</td>
<td>Deutsche Bank</td>
<td>Lowers</td>
<td>Buy</td>
<td>$110.00</td>
<td>$135.00</td>
</tr>
<tr>
<td>Kieran De Brun</td>
<td>Mizuho</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$120.00</td>
<td>$132.00</td>
</tr>
<tr>
<td>Michael Sison</td>
<td>Wells Fargo</td>
<td>Lowers</td>
<td>Equal-Weight</td>
<td>$115.00</td>
<td>$165.00</td>
</tr>
<tr>
<td>Kevin McCarthy</td>
<td>Vertical Research</td>
<td>Announces</td>
<td>Sell</td>
<td>$130.00</td>
<td>-</td>
</tr>
<tr>
<td>Arun Viswanathan</td>
<td>RBC Capital</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$163.00</td>
<td>$167.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li><strong>Action Taken:</strong> Analysts respond to changes in market conditions and company performance, frequently updating their recommendations. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Celanese. This information offers a snapshot of how analysts perceive the current state of the company.</li>
<li><strong>Rating:</strong> Unveiling insights, analysts deliver qualitative insights into stock performance, from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Celanese compared to the broader market.</li>
<li><strong>Price Targets:</strong> Analysts predict movements in price targets, offering estimates for Celanese's future value. Examining the current and prior targets offers insights into analysts' evolving expectations.</li>
</ul>
<p>Understanding these analyst evaluations alongside key financial indicators can offer valuable insights into Celanese's market standing. Stay informed and make well-considered decisions with our Ratings Table.</p>
<p><a href="https://www.benzinga.com/quote/CE/analyst-ratings?utm_source=Benzinga Insights"><strong>Stay up to date on Celanese analyst ratings.</strong></a></p>
<h2>All You Need to Know About Celanese</h2>
<p>Celanese is one of the world's largest producers of acetic acid and its downstream derivative chemicals, which are used in various end markets, including coatings and adhesives. The company is also one of the largest producers of specialty polymers, which are used in the automotive, electronics, medical, building, and consumer end markets. The company also makes cellulose derivatives used in cigarette filters.</p>
<h3>A Deep Dive into Celanese's Financials</h3>
<p><strong>Market Capitalization:</strong> With restricted market capitalization, the company is positioned below industry averages. This reflects a smaller scale relative to peers.</p>
<p><strong>Decline in Revenue:</strong> Over the 3 months period, Celanese faced challenges, resulting in a decline of approximately <strong>-2.75%</strong> in revenue growth as of 30 September, 2024. This signifies a reduction in the company's top-line earnings. As compared to competitors, the company encountered difficulties, with a growth rate lower than the average among peers in the Materials sector.</p>
<p><strong>Net Margin:</strong> Celanese's net margin is impressive, surpassing industry averages. With a net margin of <strong>4.38%,</strong> the company demonstrates strong profitability and effective cost management.</p>
<p><strong>Return on Equity (ROE):</strong> Celanese's ROE surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive <strong>1.61%</strong> ROE, the company effectively utilizes shareholder equity capital.</p>
<p><strong>Return on Assets (ROA):</strong> Celanese's ROA is below industry standards, pointing towards difficulties in efficiently utilizing assets. With an ROA of <strong>0.45%,</strong> the company may encounter challenges in delivering satisfactory returns from its assets.</p>
<p><strong>Debt Management:</strong> With a high debt-to-equity ratio of <strong>1.83</strong>, Celanese faces challenges in effectively managing its debt levels, indicating potential financial strain.</p>
<h2>Understanding the Relevance of Analyst Ratings</h2>
<p>Benzinga tracks 150 analyst firms and reports on their stock expectations. Analysts typically arrive at their conclusions by predicting how much money a company will make in the future, usually the upcoming five years, and how risky or predictable that company's revenue streams are.</p>
<p>Analysts attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish their ratings on stocks. Analysts typically rate each stock once per quarter or whenever the company has a major update.</p>
<p>Analysts may enhance their evaluations by incorporating forecasts for metrics like growth estimates, earnings, and revenue, delivering additional guidance to investors. It is vital to acknowledge that, although experts in stocks and sectors, analysts are human and express their opinions when providing insights.</p>
<p><strong>Which Stocks Are Analysts Recommending Now?</strong></p>
<p>Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;utm_source=benzinga-insights"><strong>Click here to stay ahead of the market</strong></a>.</p>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


Analyst Ratings

Forecasting The Future: 15 Analyst Projections For Celanese

<p>Deep-pocketed investors have adopted a bearish approach towards Cava Group (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CAVA#NYSE">CAVA</a>), and it's something market players shouldn't ignore. Our tracking of public options records at Benzinga unveiled this significant move today. The identity of these investors remains unknown, but such a substantial move in CAVA usually suggests something big is about to happen.</p>
<p>We gleaned this information from our observations today when Benzinga's options scanner highlighted 13 extraordinary options activities for Cava Group. This level of activity is out of the ordinary.</p>
<p>The general mood among these heavyweight investors is divided, with 30% leaning bullish and 46% bearish. Among these notable options, 9 are puts, totaling $749,733, and 4 are calls, amounting to $164,620.</p>
<h3>Predicted Price Range</h3>
<p>After evaluating the trading volumes and Open Interest, it's evident that the major market movers are focusing on a price band between $100.0 and $200.0 for Cava Group, spanning the last three months.</p>
<h3>Insights into Volume &amp; Open Interest</h3>
<p>Examining the volume and open interest provides crucial insights into stock research. This information is key in gauging liquidity and interest levels for Cava Group's options at certain strike prices. Below, we present a snapshot of the trends in volume and open interest for calls and puts across Cava Group's significant trades, within a strike price range of $100.0 to $200.0, over the past month.</p>
<h3>Cava Group Option Volume And Open Interest Over Last 30 Days</h3>
<p><img src="https://www.benzinga.com/files/images/story/2024/1734634860_0.png" alt="Options Call Chart" /></p>
<h3>Biggest Options Spotted:</h3>
<p>
<table>
<thead>
<tr>
<th><strong>Symbol</strong></th>
<th><strong>PUT/CALL</strong></th>
<th><strong>Trade Type</strong></th>
<th><strong>Sentiment</strong></th>
<th><strong>Exp. Date</strong></th>
<th><strong>Ask</strong></th>
<th><strong>Bid</strong></th>
<th><strong>Price</strong></th>
<th><strong>Strike Price</strong></th>
<th><strong>Total Trade Price</strong></th>
<th align="right"><strong>Open Interest</strong></th>
<th align="right"><strong>Volume</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td>CAVA</td>
<td>PUT</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>01/16/26</td>
<td>$15.2</td>
<td>$15.0</td>
<td>$15.13</td>
<td>$100.00</td>
<td>$304.1K</td>
<td align="right">895</td>
<td align="right">354</td>
</tr>
<tr>
<td>CAVA</td>
<td>PUT</td>
<td>TRADE</td>
<td>NEUTRAL</td>
<td>04/17/25</td>
<td>$37.9</td>
<td>$36.7</td>
<td>$37.2</td>
<td>$150.00</td>
<td>$111.6K</td>
<td align="right">234</td>
<td align="right">30</td>
</tr>
<tr>
<td>CAVA</td>
<td>PUT</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>02/21/25</td>
<td>$15.9</td>
<td>$15.7</td>
<td>$15.9</td>
<td>$130.00</td>
<td>$79.5K</td>
<td align="right">739</td>
<td align="right">51</td>
</tr>
<tr>
<td>CAVA</td>
<td>PUT</td>
<td>TRADE</td>
<td>NEUTRAL</td>
<td>01/16/26</td>
<td>$30.9</td>
<td>$30.1</td>
<td>$30.5</td>
<td>$130.00</td>
<td>$76.2K</td>
<td align="right">137</td>
<td align="right">0</td>
</tr>
<tr>
<td>CAVA</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>12/20/24</td>
<td>$2.35</td>
<td>$2.15</td>
<td>$2.35</td>
<td>$118.00</td>
<td>$70.2K</td>
<td align="right">20</td>
<td align="right">302</td>
</tr>
</tbody>
</table>
</p>
<h3>About Cava Group</h3>
<p>Cava Group Inc owns and operates a chain of restaurants. It is the category-defining Mediterranean fast-casual restaurant brand, bringing together healthful food and bold, satisfying flavors at scale. The company's dips, spreads, and dressings are centrally produced and sold in grocery stores. The company's operations are conducted as two reportable segments: CAVA and Zoes Kitchen. The company generates the majority of its revenue from the CAVA segment.</p>
<p>Having examined the options trading patterns of Cava Group, our attention now turns directly to the company. This shift allows us to delve into its present market position and performance</p>
<h3>Cava Group's Current Market Status</h3>
<ul>
<li>With a volume of 1,605,011, the price of CAVA is up 0.26% at $117.5. </li>
<li>RSI indicators hint that the underlying stock may be oversold.</li>
<li>Next earnings are expected to be released in 68 days.</li>
</ul>
<h3>What Analysts Are Saying About Cava Group</h3>
<p>A total of 1 professional analysts have given their take on this stock in the last 30 days, setting an average price target of $145.0.</p>
<p><strong>Unusual Options Activity Detected: Smart Money on the Move</strong></p>
<p>Benzinga Edge's Unusual Options board spots potential market movers before they happen. See what positions big money is taking on your favorite stocks. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=Be8be9arja3be22bz20&amp;utm_source=benzinga-insights"><strong>Click here for access</strong></a>.<br />
&#x2A; An analyst from Bernstein downgraded its action to Market Perform with a price target of $145. </p>
<p>Options are a riskier asset compared to just trading the stock, but they have higher profit potential. Serious options traders manage this risk by educating themselves daily, scaling in and out of trades, following more than one indicator, and following the markets closely.</p>
<p>If you want to stay updated on the latest options trades for Cava Group, <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a> gives you real-time options trades alerts.</p>


CAVA

Spotlight on Cava Group: Analyzing the Surge in Options Activity

<p>Analysts' ratings for Targa Resources (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TRGP#NYSE">TRGP</a>) over the last quarter vary from bullish to bearish, as provided by 14 analysts.</p>
<p>The following table encapsulates their recent ratings, offering a glimpse into the evolving sentiments over the past 30 days and comparing them to the preceding months.</p>
<table>
<thead>
<tr>
<th></th>
<th align="right"><strong>Bullish</strong></th>
<th align="right"><strong>Somewhat Bullish</strong></th>
<th align="right"><strong>Indifferent</strong></th>
<th align="right"><strong>Somewhat Bearish</strong></th>
<th align="right"><strong>Bearish</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Total Ratings</strong></td>
<td align="right">8</td>
<td align="right">6</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>Last 30D</strong></td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>1M Ago</strong></td>
<td align="right">2</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>2M Ago</strong></td>
<td align="right">4</td>
<td align="right">3</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>3M Ago</strong></td>
<td align="right">1</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
<p>Insights from analysts' 12-month price targets are revealed, presenting an average target of $200.5, a high estimate of $246.00, and a low estimate of $171.00. Observing a 16.15% increase, the current average has risen from the previous average price target of $172.62. </p>
<p><img src="https://www.benzinga.com/files/images/story/2024/1734634854_0.png" alt="price target chart" /></p>
<h2>Decoding Analyst Ratings: A Detailed Look</h2>
<p>An in-depth analysis of recent analyst actions unveils how financial experts perceive Targa Resources. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.</p>
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>John Mackay</td>
<td>Goldman Sachs</td>
<td>Raises</td>
<td>Buy</td>
<td>$223.00</td>
<td>$185.00</td>
</tr>
<tr>
<td>Michael Blum</td>
<td>Wells Fargo</td>
<td>Raises</td>
<td>Overweight</td>
<td>$204.00</td>
<td>$190.00</td>
</tr>
<tr>
<td>Neal Dingmann</td>
<td>Truist Securities</td>
<td>Lowers</td>
<td>Buy</td>
<td>$220.00</td>
<td>$225.00</td>
</tr>
<tr>
<td>Selman Akyol</td>
<td>Stifel</td>
<td>Raises</td>
<td>Buy</td>
<td>$224.00</td>
<td>$190.00</td>
</tr>
<tr>
<td>Shneur Gershuni</td>
<td>UBS</td>
<td>Raises</td>
<td>Buy</td>
<td>$246.00</td>
<td>$182.00</td>
</tr>
<tr>
<td>Neal Dingmann</td>
<td>Truist Securities</td>
<td>Raises</td>
<td>Buy</td>
<td>$225.00</td>
<td>$175.00</td>
</tr>
<tr>
<td>Elvira Scotto</td>
<td>RBC Capital</td>
<td>Raises</td>
<td>Outperform</td>
<td>$199.00</td>
<td>$172.00</td>
</tr>
<tr>
<td>Michael Blum</td>
<td>Wells Fargo</td>
<td>Raises</td>
<td>Overweight</td>
<td>$190.00</td>
<td>$153.00</td>
</tr>
<tr>
<td>Neal Dingmann</td>
<td>Truist Securities</td>
<td>Raises</td>
<td>Buy</td>
<td>$175.00</td>
<td>$150.00</td>
</tr>
<tr>
<td>Sunil Sibal</td>
<td>Seaport Global</td>
<td>Raises</td>
<td>Buy</td>
<td>$174.00</td>
<td>$141.00</td>
</tr>
<tr>
<td>Robert Kad</td>
<td>Morgan Stanley</td>
<td>Raises</td>
<td>Overweight</td>
<td>$202.00</td>
<td>$173.00</td>
</tr>
<tr>
<td>Jean Ann Salisbury</td>
<td>B of A Securities</td>
<td>Announces</td>
<td>Buy</td>
<td>$182.00</td>
<td>-</td>
</tr>
<tr>
<td>Elvira Scotto</td>
<td>RBC Capital</td>
<td>Raises</td>
<td>Outperform</td>
<td>$172.00</td>
<td>$153.00</td>
</tr>
<tr>
<td>Christine Cho</td>
<td>Barclays</td>
<td>Raises</td>
<td>Overweight</td>
<td>$171.00</td>
<td>$155.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li><strong>Action Taken:</strong> Analysts adapt their recommendations to changing market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their response to recent developments related to Targa Resources. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li><strong>Rating:</strong> Offering insights into predictions, analysts assign qualitative values, from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Targa Resources compared to the broader market.</li>
<li><strong>Price Targets:</strong> Gaining insights, analysts provide estimates for the future value of Targa Resources's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
<p>Navigating through these analyst evaluations alongside other financial indicators can contribute to a holistic understanding of Targa Resources's market standing. Stay informed and make data-driven decisions with our Ratings Table.</p>
<p><a href="https://www.benzinga.com/quote/TRGP/analyst-ratings?utm_source=Benzinga Insights"><strong>Stay up to date on Targa Resources analyst ratings.</strong></a></p>
<h2>About Targa Resources</h2>
<p>Targa Resources is a midstream firm that primarily operates gathering and processing assets with substantial positions in the Permian, Stack, Scoop, and Bakken plays. It has fractionation capacity at Mont Belvieu and operates a liquefied petroleum gas export terminal. The Grand Prix natural gas liquids pipeline is another important asset.</p>
<h3>Targa Resources: Delving into Financials</h3>
<p><strong>Market Capitalization:</strong> Boasting an elevated market capitalization, the company surpasses industry averages. This signals substantial size and strong market recognition.</p>
<p><strong>Revenue Growth:</strong> Targa Resources's revenue growth over a period of 3 months has faced challenges. As of 30 September, 2024, the company experienced a revenue decline of approximately <strong>-1.15%</strong>. This indicates a decrease in the company's top-line earnings. When compared to others in the Energy sector, the company faces challenges, achieving a growth rate lower than the average among peers.</p>
<p><strong>Net Margin:</strong> Targa Resources's net margin is below industry standards, pointing towards difficulties in achieving strong profitability. With a net margin of <strong>9.98%,</strong> the company may encounter challenges in effective cost control.</p>
<p><strong>Return on Equity (ROE):</strong> Targa Resources's ROE excels beyond industry benchmarks, reaching <strong>15.25%</strong>. This signifies robust financial management and efficient use of shareholder equity capital.</p>
<p><strong>Return on Assets (ROA):</strong> Targa Resources's financial strength is reflected in its exceptional ROA, which exceeds industry averages. With a remarkable ROA of <strong>1.78%,</strong> the company showcases efficient use of assets and strong financial health.</p>
<p><strong>Debt Management:</strong> Targa Resources's debt-to-equity ratio surpasses industry norms, standing at <strong>5.57</strong>. This suggests the company carries a substantial amount of debt, posing potential financial challenges.</p>
<h2>The Core of Analyst Ratings: What Every Investor Should Know</h2>
<p>Experts in banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their comprehensive research involves attending company conference calls and meetings, analyzing financial statements, and engaging with insiders to generate what are known as analyst ratings for stocks. Typically, analysts assess and rate each stock once per quarter.</p>
<p>In addition to their assessments, some analysts extend their insights by offering predictions for key metrics such as earnings, revenue, and growth estimates. This supplementary information provides further guidance for traders. It is crucial to recognize that, despite their specialization, analysts are human and can only provide forecasts based on their beliefs.</p>
<p><strong>Which Stocks Are Analysts Recommending Now?</strong></p>
<p>Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;utm_source=benzinga-insights"><strong>Click here to stay ahead of the market</strong></a>.</p>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


TRGP

What Analysts Are Saying About Targa Resources Stock

<p>Ratings for Civitas Resources (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CIVI#NYSE">CIVI</a>) were provided by 8 analysts in the past three months, showcasing a mix of bullish and bearish perspectives.</p>
<p>The table below summarizes their recent ratings, showcasing the evolving sentiments within the past 30 days and comparing them to the preceding months.</p>
<table>
<thead>
<tr>
<th></th>
<th align="right"><strong>Bullish</strong></th>
<th align="right"><strong>Somewhat Bullish</strong></th>
<th align="right"><strong>Indifferent</strong></th>
<th align="right"><strong>Somewhat Bearish</strong></th>
<th align="right"><strong>Bearish</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Total Ratings</strong></td>
<td align="right">1</td>
<td align="right">6</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>Last 30D</strong></td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>1M Ago</strong></td>
<td align="right">0</td>
<td align="right">3</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>2M Ago</strong></td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>3M Ago</strong></td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
<p>Analysts have set 12-month price targets for Civitas Resources, revealing an average target of $74.62, a high estimate of $84.00, and a low estimate of $60.00. A negative shift in sentiment is evident as analysts have decreased the average price target by 10.25%. </p>
<p><img src="https://www.benzinga.com/files/images/story/2024/1734634841_0.png" alt="price target chart" /></p>
<h2>Deciphering Analyst Ratings: An In-Depth Analysis</h2>
<p>The standing of Civitas Resources among financial experts becomes clear with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.</p>
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Scott Hanold</td>
<td>RBC Capital</td>
<td>Maintains</td>
<td>Market Outperform</td>
<td>$70.00</td>
<td>$70.00</td>
</tr>
<tr>
<td>Mark Lear</td>
<td>Piper Sandler</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$73.00</td>
<td>$83.00</td>
</tr>
<tr>
<td>William Janela</td>
<td>Mizuho</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$78.00</td>
<td>$84.00</td>
</tr>
<tr>
<td>Zach Parham</td>
<td>JP Morgan</td>
<td>Raises</td>
<td>Overweight</td>
<td>$68.00</td>
<td>$66.00</td>
</tr>
<tr>
<td>Mark Lear</td>
<td>Piper Sandler</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$83.00</td>
<td>$84.00</td>
</tr>
<tr>
<td>Josh Silverstein</td>
<td>UBS</td>
<td>Announces</td>
<td>Neutral</td>
<td>$60.00</td>
<td>-</td>
</tr>
<tr>
<td>Tim Rezvan</td>
<td>Keybanc</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$84.00</td>
<td>$94.00</td>
</tr>
<tr>
<td>Neal Dingmann</td>
<td>Truist Securities</td>
<td>Lowers</td>
<td>Buy</td>
<td>$81.00</td>
<td>$101.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li><strong>Action Taken:</strong> Responding to changing market dynamics and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their response to recent developments related to Civitas Resources. This offers insight into analysts' perspectives on the current state of the company.</li>
<li><strong>Rating:</strong> Gaining insights, analysts provide qualitative assessments, ranging from 'Outperform' to 'Underperform'. These ratings reflect expectations for the relative performance of Civitas Resources compared to the broader market.</li>
<li><strong>Price Targets:</strong> Delving into movements, analysts provide estimates for the future value of Civitas Resources's stock. This analysis reveals shifts in analysts' expectations over time.</li>
</ul>
<p>To gain a panoramic view of Civitas Resources's market performance, explore these analyst evaluations alongside essential financial indicators. Stay informed and make judicious decisions using our Ratings Table.</p>
<p><a href="https://www.benzinga.com/quote/CIVI/analyst-ratings?utm_source=Benzinga Insights"><strong>Stay up to date on Civitas Resources analyst ratings.</strong></a></p>
<h2>Delving into Civitas Resources's Background</h2>
<p>Civitas Resources Inc is an independent exploration and production company engaged in the acquisition, development, and production of oil and associated liquids-rich natural gas in the Rocky Mountain region, in the Denver-Julesburg Basin of Colorado (DJ Basin). The company's operations are focused on developing the horizontal Niobrara and Codell formations that have a low-cost structure, mature infrastructure, production efficiencies, multiple producing horizons, multiple service providers, established reserves, and prospective drilling opportunities.</p>
<h3>Financial Milestones: Civitas Resources's Journey</h3>
<p><strong>Market Capitalization Analysis:</strong> The company exhibits a lower market capitalization profile, positioning itself below industry averages. This suggests a smaller scale relative to peers.</p>
<p><strong>Revenue Growth:</strong> Civitas Resources's remarkable performance in 3 months is evident. As of 30 September, 2024, the company achieved an impressive revenue growth rate of <strong>22.79%</strong>. This signifies a substantial increase in the company's top-line earnings. In comparison to its industry peers, the company stands out with a growth rate higher than the average among peers in the Energy sector.</p>
<p><strong>Net Margin:</strong> Civitas Resources's net margin excels beyond industry benchmarks, reaching <strong>23.25%</strong>. This signifies efficient cost management and strong financial health.</p>
<p><strong>Return on Equity (ROE):</strong> Civitas Resources's ROE surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive <strong>4.46%</strong> ROE, the company effectively utilizes shareholder equity capital.</p>
<p><strong>Return on Assets (ROA):</strong> The company's ROA is a standout performer, exceeding industry averages. With an impressive ROA of <strong>1.97%,</strong> the company showcases effective utilization of assets.</p>
<p><strong>Debt Management:</strong> With a high debt-to-equity ratio of <strong>0.73</strong>, Civitas Resources faces challenges in effectively managing its debt levels, indicating potential financial strain.</p>
<h2>The Core of Analyst Ratings: What Every Investor Should Know</h2>
<p>Analysts work in banking and financial systems and typically specialize in reporting for stocks or defined sectors. Analysts may attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish "analyst ratings" for stocks. Analysts typically rate each stock once per quarter.</p>
<p>In addition to their assessments, some analysts extend their insights by offering predictions for key metrics such as earnings, revenue, and growth estimates. This supplementary information provides further guidance for traders. It is crucial to recognize that, despite their specialization, analysts are human and can only provide forecasts based on their beliefs.</p>
<p><strong>Which Stocks Are Analysts Recommending Now?</strong></p>
<p>Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;utm_source=benzinga-insights"><strong>Click here to stay ahead of the market</strong></a>.</p>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


CIVI

Analyst Expectations For Civitas Resources's Future

<p>Analysts' ratings for IREN (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IREN#NASDAQ">IREN</a>) over the last quarter vary from bullish to bearish, as provided by 10 analysts.</p>
<p>The table below offers a condensed view of their recent ratings, showcasing the changing sentiments over the past 30 days and comparing them to the preceding months.</p>
<table>
<thead>
<tr>
<th></th>
<th align="right"><strong>Bullish</strong></th>
<th align="right"><strong>Somewhat Bullish</strong></th>
<th align="right"><strong>Indifferent</strong></th>
<th align="right"><strong>Somewhat Bearish</strong></th>
<th align="right"><strong>Bearish</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Total Ratings</strong></td>
<td align="right">5</td>
<td align="right">4</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>Last 30D</strong></td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>1M Ago</strong></td>
<td align="right">3</td>
<td align="right">2</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>2M Ago</strong></td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>3M Ago</strong></td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
<p>Analysts have set 12-month price targets for IREN, revealing an average target of $18.2, a high estimate of $23.00, and a low estimate of $14.00. This current average reflects an increase of 15.56% from the previous average price target of $15.75. </p>
<p><img src="https://www.benzinga.com/files/images/story/2024/1734634830_0.png" alt="price target chart" /></p>
<h2>Interpreting Analyst Ratings: A Closer Look</h2>
<p>A clear picture of IREN's perception among financial experts is painted with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.</p>
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Lucas Pipes</td>
<td>B. Riley Securities</td>
<td>Raises</td>
<td>Buy</td>
<td>$16.00</td>
<td>$15.00</td>
</tr>
<tr>
<td>Stephen Glagola</td>
<td>Jones Trading</td>
<td>Announces</td>
<td>Buy</td>
<td>$22.00</td>
<td>-</td>
</tr>
<tr>
<td>Reginald Smith</td>
<td>JP Morgan</td>
<td>Raises</td>
<td>Neutral</td>
<td>$15.00</td>
<td>$9.50</td>
</tr>
<tr>
<td>Paul Golding</td>
<td>Macquarie</td>
<td>Raises</td>
<td>Outperform</td>
<td>$19.00</td>
<td>$13.50</td>
</tr>
<tr>
<td>Brett Knoblauch</td>
<td>Cantor Fitzgerald</td>
<td>Raises</td>
<td>Overweight</td>
<td>$23.00</td>
<td>$20.00</td>
</tr>
<tr>
<td>Joseph Vafi</td>
<td>Canaccord Genuity</td>
<td>Raises</td>
<td>Buy</td>
<td>$17.00</td>
<td>$15.00</td>
</tr>
<tr>
<td>Mike Colonnese</td>
<td>HC Wainwright &amp; Co.</td>
<td>Raises</td>
<td>Buy</td>
<td>$16.00</td>
<td>$13.00</td>
</tr>
<tr>
<td>Brett Knoblauch</td>
<td>Cantor Fitzgerald</td>
<td>Maintains</td>
<td>Overweight</td>
<td>$20.00</td>
<td>$20.00</td>
</tr>
<tr>
<td>Brett Knoblauch</td>
<td>Cantor Fitzgerald</td>
<td>Maintains</td>
<td>Overweight</td>
<td>$20.00</td>
<td>$20.00</td>
</tr>
<tr>
<td>Darren Aftahi</td>
<td>Roth MKM</td>
<td>Announces</td>
<td>Buy</td>
<td>$14.00</td>
<td>-</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li><strong>Action Taken:</strong> In response to dynamic market conditions and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their reaction to recent developments related to IREN. This insight gives a snapshot of analysts' perspectives on the current state of the company.</li>
<li><strong>Rating:</strong> Offering a comprehensive view, analysts assess stocks qualitatively, spanning from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of IREN compared to the broader market.</li>
<li><strong>Price Targets:</strong> Analysts provide insights into price targets, offering estimates for the future value of IREN's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
<p>Assessing these analyst evaluations alongside crucial financial indicators can provide a comprehensive overview of IREN's market position. Stay informed and make well-judged decisions with the assistance of our Ratings Table.</p>
<p><a href="https://www.benzinga.com/quote/IREN/analyst-ratings?utm_source=Benzinga Insights"><strong>Stay up to date on IREN analyst ratings.</strong></a></p>
<h2>Discovering IREN: A Closer Look</h2>
<p>IREN Ltd is engaged in data center business powering the future of Bitcoin, AI and beyond utilizing renewable energy.</p>
<h3>Key Indicators: IREN's Financial Health</h3>
<p><strong>Market Capitalization Perspectives:</strong> The company's market capitalization falls below industry averages, signaling a relatively smaller size compared to peers. This positioning may be influenced by factors such as perceived growth potential or operational scale.</p>
<p><strong>Revenue Growth:</strong> IREN's revenue growth over a period of 3 months has been noteworthy. As of 30 September, 2024, the company achieved a revenue growth rate of approximately <strong>58.12%</strong>. This indicates a substantial increase in the company's top-line earnings. As compared to competitors, the company surpassed expectations with a growth rate higher than the average among peers in the Information Technology sector.</p>
<p><strong>Net Margin:</strong> IREN's financial strength is reflected in its exceptional net margin, which exceeds industry averages. With a remarkable net margin of <strong>-95.07%,</strong> the company showcases strong profitability and effective cost management.</p>
<p><strong>Return on Equity (ROE):</strong> IREN's ROE falls below industry averages, indicating challenges in efficiently using equity capital. With an ROE of <strong>-4.64%,</strong> the company may face hurdles in generating optimal returns for shareholders.</p>
<p><strong>Return on Assets (ROA):</strong> IREN's ROA lags behind industry averages, suggesting challenges in maximizing returns from its assets. With an ROA of <strong>-4.25%,</strong> the company may face hurdles in achieving optimal financial performance.</p>
<p><strong>Debt Management:</strong> The company maintains a balanced debt approach with a debt-to-equity ratio below industry norms, standing at <strong>0.0</strong>.</p>
<h2>The Significance of Analyst Ratings Explained</h2>
<p>Analysts work in banking and financial systems and typically specialize in reporting for stocks or defined sectors. Analysts may attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish "analyst ratings" for stocks. Analysts typically rate each stock once per quarter.</p>
<p>Some analysts also offer predictions for helpful metrics such as earnings, revenue, and growth estimates to provide further guidance as to what to do with certain tickers. It is important to keep in mind that while stock and sector analysts are specialists, they are also human and can only forecast their beliefs to traders.</p>
<p><strong>Which Stocks Are Analysts Recommending Now?</strong></p>
<p>Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;utm_source=benzinga-insights"><strong>Click here to stay ahead of the market</strong></a>.</p>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


IREN

Expert Outlook: IREN Through The Eyes Of 10 Analysts

<p>Ratings for Deere (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DE#NYSE">DE</a>) were provided by 12 analysts in the past three months, showcasing a mix of bullish and bearish perspectives.</p>
<p>The table below provides a snapshot of their recent ratings, showcasing how sentiments have evolved over the past 30 days and comparing them to the preceding months.</p>
<table>
<thead>
<tr>
<th></th>
<th align="right"><strong>Bullish</strong></th>
<th align="right"><strong>Somewhat Bullish</strong></th>
<th align="right"><strong>Indifferent</strong></th>
<th align="right"><strong>Somewhat Bearish</strong></th>
<th align="right"><strong>Bearish</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Total Ratings</strong></td>
<td align="right">3</td>
<td align="right">3</td>
<td align="right">6</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>Last 30D</strong></td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>1M Ago</strong></td>
<td align="right">1</td>
<td align="right">3</td>
<td align="right">4</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>2M Ago</strong></td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>3M Ago</strong></td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
<p>Insights from analysts' 12-month price targets are revealed, presenting an average target of $476.5, a high estimate of $550.00, and a low estimate of $420.00. Observing a 8.4% increase, the current average has risen from the previous average price target of $439.58. </p>
<p><img src="https://www.benzinga.com/files/images/story/2024/1734634822_0.png" alt="price target chart" /></p>
<h2>Decoding Analyst Ratings: A Detailed Look</h2>
<p>The standing of Deere among financial experts is revealed through an in-depth exploration of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.</p>
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Jamie Cook</td>
<td>Truist Securities</td>
<td>Raises</td>
<td>Buy</td>
<td>$550.00</td>
<td>$538.00</td>
</tr>
<tr>
<td>Kyle Menges</td>
<td>Citigroup</td>
<td>Raises</td>
<td>Neutral</td>
<td>$470.00</td>
<td>$460.00</td>
</tr>
<tr>
<td>Stephen Volkmann</td>
<td>Jefferies</td>
<td>Maintains</td>
<td>Hold</td>
<td>$510.00</td>
<td>$510.00</td>
</tr>
<tr>
<td>Angel Castillo</td>
<td>Morgan Stanley</td>
<td>Raises</td>
<td>Overweight</td>
<td>$450.00</td>
<td>$401.00</td>
</tr>
<tr>
<td>Steven Fisher</td>
<td>UBS</td>
<td>Raises</td>
<td>Neutral</td>
<td>$462.00</td>
<td>$404.00</td>
</tr>
<tr>
<td>Jamie Cook</td>
<td>Truist Securities</td>
<td>Raises</td>
<td>Buy</td>
<td>$538.00</td>
<td>$496.00</td>
</tr>
<tr>
<td>Kristen Owen</td>
<td>Oppenheimer</td>
<td>Raises</td>
<td>Outperform</td>
<td>$477.00</td>
<td>$448.00</td>
</tr>
<tr>
<td>Tami Zakaria</td>
<td>JP Morgan</td>
<td>Raises</td>
<td>Neutral</td>
<td>$450.00</td>
<td>$420.00</td>
</tr>
<tr>
<td>Adam Seiden</td>
<td>Barclays</td>
<td>Raises</td>
<td>Overweight</td>
<td>$475.00</td>
<td>$400.00</td>
</tr>
<tr>
<td>Tami Zakaria</td>
<td>JP Morgan</td>
<td>Raises</td>
<td>Neutral</td>
<td>$420.00</td>
<td>$360.00</td>
</tr>
<tr>
<td>Kyle Menges</td>
<td>Citigroup</td>
<td>Raises</td>
<td>Neutral</td>
<td>$420.00</td>
<td>$395.00</td>
</tr>
<tr>
<td>Jamie Cook</td>
<td>Truist Securities</td>
<td>Raises</td>
<td>Buy</td>
<td>$496.00</td>
<td>$443.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li><strong>Action Taken:</strong> In response to dynamic market conditions and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their reaction to recent developments related to Deere. This insight gives a snapshot of analysts' perspectives on the current state of the company.</li>
<li><strong>Rating:</strong> Offering insights into predictions, analysts assign qualitative values, from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Deere compared to the broader market.</li>
<li><strong>Price Targets:</strong> Analysts navigate through adjustments in price targets, providing estimates for Deere's future value. Comparing current and prior targets offers insights into analysts' evolving expectations.</li>
</ul>
<p>Analyzing these analyst evaluations alongside relevant financial metrics can provide a comprehensive view of Deere's market position. Stay informed and make data-driven decisions with the assistance of our Ratings Table.</p>
<p><a href="https://www.benzinga.com/quote/DE/analyst-ratings?utm_source=Benzinga Insights"><strong>Stay up to date on Deere analyst ratings.</strong></a></p>
<h2>About Deere</h2>
<p>Deere is the world's leading manufacturer of agricultural equipment, producing some of the most recognizable machines in the heavy machinery industry in their green and yellow livery. The company is divided into four reportable segments: production and precision agriculture, small agriculture and turf, construction and forestry, and John Deere Capital. Its products are available through an extensive dealer network, which includes over 2,000 dealer locations in North America and approximately 3,700 locations globally. John Deere Capital provides retail financing for machinery to its customers, in addition to wholesale financing for dealers, which increases the likelihood of Deere product sales.</p>
<h3>Deere: Delving into Financials</h3>
<p><strong>Market Capitalization Analysis:</strong> The company's market capitalization is above the industry average, indicating that it is relatively larger in size compared to peers. This may suggest a higher level of investor confidence and market recognition.</p>
<p><strong>Decline in Revenue:</strong> Over the 3 months period, Deere faced challenges, resulting in a decline of approximately <strong>-15.74%</strong> in revenue growth as of 31 October, 2024. This signifies a reduction in the company's top-line earnings. In comparison to its industry peers, the company trails behind with a growth rate lower than the average among peers in the Industrials sector.</p>
<p><strong>Net Margin:</strong> Deere's net margin excels beyond industry benchmarks, reaching <strong>11.5%</strong>. This signifies efficient cost management and strong financial health.</p>
<p><strong>Return on Equity (ROE):</strong> The company's ROE is a standout performer, exceeding industry averages. With an impressive ROE of <strong>5.43%,</strong> the company showcases effective utilization of equity capital.</p>
<p><strong>Return on Assets (ROA):</strong> Deere's ROA surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive <strong>1.16%</strong> ROA, the company effectively utilizes its assets for optimal returns.</p>
<p><strong>Debt Management:</strong> The company faces challenges in debt management with a debt-to-equity ratio higher than the industry average. With a ratio of <strong>2.85</strong>, caution is advised due to increased financial risk.</p>
<h2>Analyst Ratings: What Are They?</h2>
<p>Analysts work in banking and financial systems and typically specialize in reporting for stocks or defined sectors. Analysts may attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish "analyst ratings" for stocks. Analysts typically rate each stock once per quarter.</p>
<p>Beyond their standard evaluations, some analysts contribute predictions for metrics like growth estimates, earnings, and revenue, furnishing investors with additional guidance. Users of analyst ratings should be mindful that this specialized advice is shaped by human perspectives and may be subject to variability.</p>
<p><strong>Breaking: Wall Street's Next Big Mover</strong></p>
<p>Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;utm_source=benzinga-insights"><strong>Click here for urgent details</strong></a>.</p>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


A Glimpse Into The Expert Outlook On Deere Through 12 Analysts

<p>Ratings for East West Bancorp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EWBC#NASDAQ">EWBC</a>) were provided by 18 analysts in the past three months, showcasing a mix of bullish and bearish perspectives.</p>
<p>The table below summarizes their recent ratings, showcasing the evolving sentiments within the past 30 days and comparing them to the preceding months.</p>
<table>
<thead>
<tr>
<th></th>
<th align="right"><strong>Bullish</strong></th>
<th align="right"><strong>Somewhat Bullish</strong></th>
<th align="right"><strong>Indifferent</strong></th>
<th align="right"><strong>Somewhat Bearish</strong></th>
<th align="right"><strong>Bearish</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Total Ratings</strong></td>
<td align="right">5</td>
<td align="right">11</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>Last 30D</strong></td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>1M Ago</strong></td>
<td align="right">1</td>
<td align="right">3</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>2M Ago</strong></td>
<td align="right">4</td>
<td align="right">4</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>3M Ago</strong></td>
<td align="right">0</td>
<td align="right">3</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
<p>Analysts have set 12-month price targets for East West Bancorp, revealing an average target of $110.67, a high estimate of $128.00, and a low estimate of $95.00. Surpassing the previous average price target of $100.89, the current average has increased by 9.69%.</p>
<p><img src="https://www.benzinga.com/files/images/story/2024/1734634815_0.png" alt="price target chart" /></p>
<h2>Breaking Down Analyst Ratings: A Detailed Examination</h2>
<p>The standing of East West Bancorp among financial experts is revealed through an in-depth exploration of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.</p>
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Jared Shaw</td>
<td>Barclays</td>
<td>Raises</td>
<td>Overweight</td>
<td>$125.00</td>
<td>$120.00</td>
</tr>
<tr>
<td>Nicholas Holowko</td>
<td>UBS</td>
<td>Raises</td>
<td>Neutral</td>
<td>$112.00</td>
<td>$100.00</td>
</tr>
<tr>
<td>Dave Rochester</td>
<td>Compass Point</td>
<td>Raises</td>
<td>Buy</td>
<td>$125.00</td>
<td>$110.00</td>
</tr>
<tr>
<td>Jared Shaw</td>
<td>Barclays</td>
<td>Raises</td>
<td>Overweight</td>
<td>$120.00</td>
<td>$110.00</td>
</tr>
<tr>
<td>Christopher Mcgratty</td>
<td>Keefe, Bruyette &amp; Woods</td>
<td>Raises</td>
<td>Outperform</td>
<td>$128.00</td>
<td>$96.00</td>
</tr>
<tr>
<td>Timur Braziler</td>
<td>Wells Fargo</td>
<td>Raises</td>
<td>Overweight</td>
<td>$120.00</td>
<td>$105.00</td>
</tr>
<tr>
<td>Andrew Terrell</td>
<td>Stephens &amp; Co.</td>
<td>Raises</td>
<td>Overweight</td>
<td>$104.00</td>
<td>$91.00</td>
</tr>
<tr>
<td>Dave Rochester</td>
<td>Compass Point</td>
<td>Raises</td>
<td>Buy</td>
<td>$110.00</td>
<td>$93.00</td>
</tr>
<tr>
<td>Gary Tenner</td>
<td>DA Davidson</td>
<td>Raises</td>
<td>Buy</td>
<td>$107.00</td>
<td>$100.00</td>
</tr>
<tr>
<td>David Chiaverini</td>
<td>Wedbush</td>
<td>Raises</td>
<td>Outperform</td>
<td>$110.00</td>
<td>$100.00</td>
</tr>
<tr>
<td>Timur Braziler</td>
<td>Wells Fargo</td>
<td>Raises</td>
<td>Overweight</td>
<td>$105.00</td>
<td>$97.00</td>
</tr>
<tr>
<td>Ben Gerlinger</td>
<td>Citigroup</td>
<td>Raises</td>
<td>Buy</td>
<td>$109.00</td>
<td>$103.00</td>
</tr>
<tr>
<td>Brandon King</td>
<td>Truist Securities</td>
<td>Raises</td>
<td>Buy</td>
<td>$101.00</td>
<td>$93.00</td>
</tr>
<tr>
<td>Matthew Clark</td>
<td>Piper Sandler</td>
<td>Raises</td>
<td>Neutral</td>
<td>$95.00</td>
<td>$87.00</td>
</tr>
<tr>
<td>Jared Shaw</td>
<td>Barclays</td>
<td>Raises</td>
<td>Overweight</td>
<td>$110.00</td>
<td>$108.00</td>
</tr>
<tr>
<td>Timur Braziler</td>
<td>Wells Fargo</td>
<td>Raises</td>
<td>Overweight</td>
<td>$97.00</td>
<td>$95.00</td>
</tr>
<tr>
<td>Manan Gosalia</td>
<td>Morgan Stanley</td>
<td>Raises</td>
<td>Overweight</td>
<td>$106.00</td>
<td>$103.00</td>
</tr>
<tr>
<td>Jared Shaw</td>
<td>Barclays</td>
<td>Raises</td>
<td>Overweight</td>
<td>$108.00</td>
<td>$105.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li><strong>Action Taken:</strong> Analysts respond to changes in market conditions and company performance, frequently updating their recommendations. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to East West Bancorp. This information offers a snapshot of how analysts perceive the current state of the company.</li>
<li><strong>Rating:</strong> Analyzing trends, analysts offer qualitative evaluations, ranging from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of East West Bancorp compared to the broader market.</li>
<li><strong>Price Targets:</strong> Gaining insights, analysts provide estimates for the future value of East West Bancorp's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
<p>Navigating through these analyst evaluations alongside other financial indicators can contribute to a holistic understanding of East West Bancorp's market standing. Stay informed and make data-driven decisions with our Ratings Table.</p>
<p><a href="https://www.benzinga.com/quote/EWBC/analyst-ratings?utm_source=Benzinga Insights"><strong>Stay up to date on East West Bancorp analyst ratings.</strong></a></p>
<h2>Unveiling the Story Behind East West Bancorp</h2>
<p>East West Bancorp Inc is the holding company for East West Bank, a full-service commercial bank with cross-border operations concentrated in the United States and China. East-West Bank is one of a few U.S. based banks with a full banking license in China. The bank's cost strategy has increasingly focused on expanding its deposit base away from time deposits to commercial deposits. The bank has also taken part in entertainment partnerships between participants in China and Hollywood. Most of these efforts include financing the production and distribution of film and television projects. The bank leverages its cultural and regulatory knowledge in the U.S. and China to assist its customers in entering new markets. Most of its earning assets are in loans held for investment.</p>
<h3>Key Indicators: East West Bancorp's Financial Health</h3>
<p><strong>Market Capitalization:</strong> Boasting an elevated market capitalization, the company surpasses industry averages. This signals substantial size and strong market recognition.</p>
<p><strong>Positive Revenue Trend:</strong> Examining East West Bancorp's financials over 3 months reveals a positive narrative. The company achieved a noteworthy revenue growth rate of <strong>1.46%</strong> as of 30 September, 2024, showcasing a substantial increase in top-line earnings. When compared to others in the Financials sector, the company faces challenges, achieving a growth rate lower than the average among peers.</p>
<p><strong>Net Margin:</strong> East West Bancorp's net margin surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive <strong>46.36%</strong> net margin, the company effectively manages costs and achieves strong profitability.</p>
<p><strong>Return on Equity (ROE):</strong> East West Bancorp's ROE surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive <strong>4.02%</strong> ROE, the company effectively utilizes shareholder equity capital.</p>
<p><strong>Return on Assets (ROA):</strong> East West Bancorp's ROA surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive <strong>0.41%</strong> ROA, the company effectively utilizes its assets for optimal returns.</p>
<p><strong>Debt Management:</strong> The company maintains a balanced debt approach with a debt-to-equity ratio below industry norms, standing at <strong>0.47</strong>.</p>
<h2>The Core of Analyst Ratings: What Every Investor Should Know</h2>
<p>Analysts are specialists within banking and financial systems that typically report for specific stocks or within defined sectors. These people research company financial statements, sit in conference calls and meetings, and speak with relevant insiders to determine what are known as analyst ratings for stocks. Typically, analysts will rate each stock once a quarter. </p>
<p>Some analysts will also offer forecasts for metrics like growth estimates, earnings, and revenue to provide further guidance on stocks. Investors who use analyst ratings should note that this specialized advice comes from humans and may be subject to error.</p>
<p><strong>Which Stocks Are Analysts Recommending Now?</strong></p>
<p>Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;utm_source=benzinga-insights"><strong>Click here to stay ahead of the market</strong></a>.</p>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


EWBC

Forecasting The Future: 18 Analyst Projections For East West Bancorp

<p>The electric vehicle market lost some juice earlier in 2024, but October showed a sector comeback with some serious battery power.</p>
<p>According to Cox Automotive, new EV sales were up 2.3% for the month and have cleared one million units for the year to date. Cox attributed the growth to aggressive dealer incentives and attractive vehicle leasing deals.</p>
<p>But that growth has yet to translate into success for sector portfolio players. A case in point is the benchmark Global X Autonomous &amp; Electric Vehicles ETF (DRIV), which is losing ground, down -6.61% for the year.</p>
<p>That's the trouble with EV stocks and funds, market mavens say. While the long-term glide path looks clear enough for electric vehicles, mile marker to mile marker, the sector isn't gaining much steam.</p>
<p><strong>Here&#8217;s why those troubles may continue in 2025 &#8211; with one huge potential exception.</strong></p>
<p>&#8220;There is a lot of opportunity in the EV market, but it still faces significant challenges, mainly geared around consumer confusion," says David Boice, CEO of Team Velocity, an automotive technologies firm in Washington, D.C.<strong> </strong>&nbsp;"The upsides are that EVs are changing how the government can incentivize vehicles, allowing OEMs to explore new tech, and cities are constantly expanding infrastructure for mass adoption and sustainability."</p>
<p>The downsides, unfortunately, are stacking up right now.</p>
<p>"A lack of resources leaves consumers uncertain; tax credits, charging time, and long-term savings are all things Americans need to understand before buying an EV," Boice says. "OEMs and dealers need to be providing clear messaging about their vehicles to make sure there is as little friction surrounding the EV purchasing process as possible.&#8221;</p>
<p>Another issue vexing potential investors is how the Trump administration's EV policies will play out.</p>
<p>"The biggest downsides right now have to do with affordability," says  KC Boyce, vice president at Escalent, a global market research and data advisory firm. "If the EV purchase tax credit goes away under Trump 2.0 and automakers don't continue a relentless pursuit of affordable models, EV adoption will run out of juice."</p>
<p><strong><a href="https://www.benzinga.com/pro/checkout/benzinga-pro-essential-2024/?t=be16bespmirebz36&amp;utm_source=WebRD-1219">[Two-Week Free Access to Pro-Level Trading Tools]</a></strong></p>
<p><strong>What the Experts Are Saying About EV Stocks</strong></p>
<p>With that framework in mind, where are EV stocks headed in what promises to be a tumultuous 2025? Here's a snapshot of what sector plays stand out and why.</p>
<p><strong>Tesla (TSLA).</strong> Elon Musk's favorite car company has seen its share price rise by 34% so far in 2024, comfortably ahead of the S&amp;P 500 Index, which is up 26% for the year.</p>
<p>When it comes to investing, companies that show they're in it for the long haul are almost always a good bet, and Tesla follows that script to the letter.</p>
<p>"Tesla is an obvious choice as an EV favorite — they've practically defined the electric vehicles category," says Mark Whitley, founder and CEO at Whits Corporation, a sustainable technology firm in St. Louis, Mo.</p>
<p>Investors shouldn't pay too much attention to the highly vocal Musk, but the Trump administration's aggressive stance on tariffs and EV credits is another story.&nbsp; "Despite Elon Musk saying he wants Trump to kill EV tax credits, Tesla benefits greatly from the current regulatory regime," Boyce says.</p>
<p><strong>Chargeback (CHPT).</strong> This Campbell, Cal.-based electric vehicle charging network provider went public last March via a special purchase acquisition company (SPAC) deal and has plummeted over 90% since the rollout.</p>
<p>Yet the company operates 315,000 charging ports in the US and abroad, giving it a big advantage in a burgeoning industry. It also has over one million roaming charging points, which represents a robust number in another growing EV sector.</p>
<p>The company's broad-based operational stance should eventually stabilize the stock price, but it also has other advantages.</p>
<p>"Let's not forget the infrastructure part," Whitley says. "Companies like ChargePoint, which focuses on electric vehicle charging solutions, are a way to invest in the sector without betting on any specific vehicle."</p>
<p><strong>BHP Group, LTD (BHP).</strong> This nickel mining company is a good supply/demand stock right now, as nickel is one EV-linked commodity company that can take advantage of rising EV battery needs.</p>
<p>The stock is down 24% for the year, but with production pressures pushing nickel demand up, BHP may make sense for sector investors over the long haul.</p>
<p>"There's potential in businesses that develop EV infrastructure, like battery technology and charging networks," says Dre Villeroy, CEO at Beyorch, a private equity firm in Los Angeles, Cal. "They are essential to expanding the sector."</p>
<p><strong>Going Forward</strong></p>
<p>Ultimately, investors' short-term sector issues against long-term potential will matter most, and lead them to choose sector stocks accordingly.</p>
<p>"I suspect EV sales will be very strong in December due to the prospect of the tax credit going away and may slow down for a bit as the ultimate resolution of the tax credit is under discussion in Washington," Boyce says. "Over time, however, EVs will continue a growth trajectory."</p>
<p>"Just how quick a growth trajectory really depends on where we land with the regulatory and tax environment in Washington," he adds.</p>
<p>Step up your trading with Benzinga Pro's advanced news alerts, scanners, and real-time market insights. Join over 6,000 traders who rely on these tools to spot opportunities first. <strong><a href="https://www.benzinga.com/pro/checkout/benzinga-pro-essential-2024/?t=be16bespmirebz36&amp;utm_source=WebRD-1219">Start your free trial and trade smarter today.</a></strong></p>
<p>Image via Shutterstock</p>


Opinion

Where EV Stocks Are Going In 2025

WIIM

QBTS

QMCO

QUBT

RGTI

Shares of quantum computing companies are trading lower. The industry may be pulling back following recent strength.

Macro Economic Events

Market Summary

Economics

Benzinga Market Summary: S&P Rises Following GDP And Jobless Claims Data

<p><strong>Nike Inc </strong>(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NKE#NYSE">NKE</a>) will be reporting its second-quarter earnings on Thursday. Wall Street expects 64 cents in EPS and $12.13 billion in revenues as the company reports<a href="https://www.benzinga.com/calendars/earnings?tickers=NKE" target="_blank" rel="noreferrer noopener"> after market hours</a>.</p>
<p>The stock is down 37.30% over the past year, 19.54% over the past six months. </p>
<h1 class="wp-block-heading"><strong>Nike Facing Slowing Growth, Stock Slipping</strong></h1>
<p>Nike has faced consistent challenges in recent quarters, with growth slowing and stock performance reflecting the headwinds. </p>
<p>Shares have gapped down after earnings in four consecutive reports, including October, when the company missed revenue expectations and withdrew its full-year guidance. </p>
<p>Weakness in North America and China, coupled with a 15% drop in digital sales and a 13% decline in direct-to-consumer sales, has weighed heavily on results. Nike's strategic pivot to prioritize direct sales over wholesale channels like <strong>Foot Locker Inc</strong> (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FL#NYSE">FL</a>) and <strong>DSW</strong> has yet to deliver the desired rebound, leaving investors cautious ahead of its upcoming earnings release.</p>
<p>Let&#8217;s look at what the charts indicate for Nike stock and how the stock currently maps against Wall Street estimates.</p>
<p><strong>Read Also: <a href="https://www.benzinga.com/analyst-ratings/analyst-color/24/12/42562515/nike-q2-earnings-preview-analyst-says-athletic-brand-early-in-turnaround-journey-with-new-ceo">Nike Q2 Earnings Preview: Analyst Says Athletic Brand Early In &#8216;Turnaround Journey&#8217; With New CEO</a></strong></p>
<h1 class="wp-block-heading"><strong>Nike Stock Chart Bearish Ahead Of Q2 Earnings&nbsp;</strong></h1>
<p>Nike&#8217;s technical indicators paint a bearish picture ahead of its earnings release. </p>
<p><figure class="wp-block-image size-full"><a href="https://bzresearch.myclickfunnels.com/benzinga-pro-content-webinar-registration/?utm_source=BZprocontent121924&amp;t=be2bearmibe3na1"><img loading="lazy" decoding="async" width="630" height="493" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/12/19064511/Screenshot-2024-12-19-at-4.40.59-PM.png" alt="" class="wp-image-699488" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2024/12/19064511/Screenshot-2024-12-19-at-4.40.59-PM.png 630w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/12/19064511/Screenshot-2024-12-19-at-4.40.59-PM-300x235.png 300w" sizes="(max-width: 630px) 100vw, 630px" /></a></figure></p>
<p><a href="https://bzresearch.myclickfunnels.com/benzinga-pro-content-webinar-registration/?utm_source=BZprocontent121924&amp;t=be2bearmibe3na1"><em>Chart created using Benzinga Pro</em></a></p>
<p>The stock is trading below its eight-day, 20-day and 50-day exponential moving averages, signaling strong bearish momentum and sustained selling pressure. With Nike stock at $76.90, below the eight-day simple moving average (SMA) of $77.57, 20-day SMA of $77.69, 50-day SMA of $78.35 and 200-day SMA of $84.77, the trend points to potential for further downside.</p>
<p>The moving average convergence/divergence (MACD) indicator at a negative 0.12 confirms a bearish signal, while the relative strength index (RSI) at 46.09 suggests the stock is approaching oversold territory but remains neutral for now.</p>
<h1 class="wp-block-heading"><strong>Nike Analysts See 17% Upside</strong></h1>
<p><strong>Ratings &amp; Consensus Estimates:</strong><a href="https://www.benzinga.com/quote/NKE/analyst-ratings" target="_blank" rel="noreferrer noopener"> The consensus analyst rating</a> on Nike stock stands at an Outperform currently with a price target of $94.10. The latest analyst ratings from Wells Fargo, Evercore ISI Group and Deutsche Bank suggest an average price target of $90.33 for Nike stock, implying a 17% upside potential.</p>
<p><strong>NKE Price Action: </strong>Nike stock is down 0.065% at $76.85 at publication on Thursday.</p>
<p><strong>Read Next: </strong></p>
<ul>
<li><strong><a href="https://www.benzinga.com/news/earnings/24/12/42569953/dow-dips-over-1100-points-falling-for-10th-session-as-powell-adopts-hawkish-stance-greed-index-moves-to-fear-zone">Dow Dips Over 1,100 Points, Falling For 10th Session As Powell Adopts Hawkish Stance: Greed Index Moves To &#8216;Fear&#8217; Zone</a></strong></li>
</ul>
<p><em>Photo: Pixfly on Shutterstock</em></p>


Previews

Nike's Earnings Loom With Bearish Signals: Will The Swoosh Bounce Back?

Psyence Biomedical shares are trading higher. The company announced it has entered into an IP licensing and mutual exclusivity agreement with Optimi Health Corp.

<p>Barrington Research  analyst Gary Prestopino   maintains Kadant (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KAI#NYSE">KAI</a>) with a Outperform and raises the price target from $360 to $410.</p>


Price Target

Barrington Research Maintains Outperform on Kadant, Raises Price Target to $410

<p>On Thursday, <strong>Merck&nbsp;&amp; Co Inc </strong>(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MRK#NYSE">MRK</a>) revealed topline results from two pivotal Phase 3 trials of a two-drug regimen of doravirine/islatravir (DOR/ISL) in adults <a target="_blank" href="https://www.benzinga.com/pressreleases/24/12/b42572326/merck-announces-topline-results-from-pivotal-phase-3-trials-evaluating-investigational-once-daily-" rel="noreferrer noopener">with HIV-1 infection</a>.</p>
<p>The trials included patients who were virologically suppressed on different antiretroviral therapy regimens, including antiretroviral therapy regimens [baseline antiretroviral therapy (<a target="_blank" href="https://clinicaltrials.gov/study/NCT05631093" rel="noreferrer noopener">bART</a>) and Bictegravir/​Emtricitabine/​Tenofovir Alafenamide (<a target="_blank" href="https://clinicaltrials.gov/study/NCT05630755" rel="noreferrer noopener">BIC/​FTC/​TAF</a>).</p>
<p>DOR/ISL was demonstrated to be non-inferior to bART in open-label trial MK-8591A-051 and non-inferior to BIC/FTC/TAF in double-blind trial MK-8591A-052.</p>
<p><strong>Also Read: <a target="_blank" href="https://www.benzinga.com/general/biotech/24/10/41434127/gilead-sciencesmercks-investigational-once-weekly-hiv-combo-therapy-shows-sustained-virus-suppres" rel="noreferrer noopener">Gilead Sciences/Merck&#8217;s Investigational Once-Weekly HIV Combo Therapy Shows Sustained Virus Suppression To 48 Weeks</a></strong></p>
<p>Trial MK-8591A-052 did not meet the superiority criteria, but both trials also met the primary safety objectives.</p>
<p>The company plans to present detailed findings from these trials at a future scientific congress and file the data with regulatory authorities.</p>
<p>In the U.S., doravirine is approved for the treatment of adults with HIV-1 in combination with other antiretrovirals, as a single agent (PIFELTRO) and a component of a single-tablet regimen [DELSTRIGO; doravirine, lamivudine, and tenofovir disoproxil fumarate (DOR/3TC/TDF)].</p>
<p>Islatravir (MK-8591), Merck&#8217;s investigational drug, is being evaluated in multiple early and late-stage clinical trials in combination with other antiretroviral therapies for the treatment of HIV-1.</p>
<p>In addition to the MK-8591A-051 and MK-8591A-052 trials, ongoing Phase 3 trials of DOR/ISL include&nbsp;<a target="_blank" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fclinicaltrials.gov%2Fstudy%2FNCT05705349&amp;esheet=54169231&amp;newsitemid=20241219661570&amp;lan=en-US&amp;anchor=MK-8591A-053&amp;index=3&amp;md5=289fad4b8e112f0df5a7c56584cbba83" rel="noreferrer noopener">MK-8591A-053</a> in people with HIV who had not previously received treatment (treatment-naïve) and&nbsp;<a target="_blank" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.clinicaltrials.gov%2Fstudy%2FNCT05766501%3Fterm%3Dislatravir%26page%3D2%26rank%3D12&amp;esheet=54169231&amp;newsitemid=20241219661570&amp;lan=en-US&amp;anchor=MK-8591A-054&amp;index=4&amp;md5=93a25503967ab506b3a49091d73d2bc9" rel="noreferrer noopener">MK-8591A-054</a> evaluating open-label DOR/ISL in individuals who participated in earlier Phase 3 trials of DOR/ISL.</p>
<p><strong>Price Action:</strong> MRK stock is up 1.18% at $99.50 at last check Thursday.</p>
<p><strong>Also Read:</strong></p>
<ul>
<li><strong><a href="https://www.benzinga.com/24/12/42598735/nip-group-to-see-14-revenue-growth-in-2025-analyst-projects-solid-long-term-growth" target="_blank" rel="noreferrer noopener">From Anime To Abu Dhabi: Analyst Sees NIP Group Transforming Entertainment And Tech</a></strong></li>
</ul>
<p><em>Photo: HIV/AIDS ribbon via Shutterstock</em>.</p>


Biotech

Equities

Large Cap

Health Care

Merck's Investigational Two-Drug Regime For HIV Meets Primary Goal In Two Late-Stage Trials

<p>According to a report, U.S. healthcare spending grew by 7.5% to $4.9 trillion in 2023. The increase was fueled by higher enrollment in private health plans and expanded use of medical services, driven by legislative changes and post-pandemic rebounds in care utilization.</p>
<p>Healthcare spending accounted for 17.6% of the U.S. economy, outpacing GDP growth of 2.9%. Spending on retail prescription drugs <a target="_blank" href="https://www.healthaffairs.org/doi/full/10.1377/hlthaff.2024.01375" rel="noreferrer noopener">saw</a> the most significant rise, jumping 11.4% to $449.7 billion.</p>
<p>The report attributed this to increased use of medications for obesity and diabetes.</p>
<p><strong>Also Read: <a target="_blank" href="https://www.benzinga.com/government/regulations/24/11/41866438/donald-trumps-second-term-could-reshape-us-healthcare-system-with-major-impacts-on-affordable-care-act-and-medicare" rel="noreferrer noopener">Donald Trump&#8217;s Second Term Could Reshape US Healthcare System, With Major Impacts on Affordable Care Act And Medicare</a></strong></p>
<p>The rapid growth in spending for drugs used to treat diabetes and obesity contributed to faster overall growth in retail prescription drug expenditures and private health insurance and Medicare spending growth.</p>
<p>Hospital care spending rose 10.4% to $1.5 trillion in 2023, marking the fastest growth since 1990. Hospital discharges increased by 1.6%, with Medicare beneficiaries driving higher outpatient service utilization.</p>
<p>Spending on physician and clinical services also climbed by 7.4% to $978 billion, with private insurance and Medicare patients contributing to this rise.</p>
<p>Enrollment in private health insurance grew by 1.6%, adding 3.3 million Americans.</p>
<p>Private insurance spending surged by 11.5%, reaching $1.5 trillion and accounting for 30% of national healthcare expenditures.</p>
<p>Medicare spending grew 8.1% to $1 trillion, representing 21% of total healthcare spending. Medicaid spending, however, grew more slowly at 7.9%, reflecting the end of the COVID-19 public health emergency.</p>
<p>The report also revealed that 92.5% of Americans had health insurance in 2023, up from 92.0% in 2022, underscoring the broader coverage expansion in recent years.</p>
<p><strong>Read Next:</strong></p>
<ul>
<li><strong><a href="https://www.benzinga.com/trading-ideas/24/12/42599673/amazon-has-20000-rivian-electric-delivery-vans-in-fleet-heres-what-could-be-next-for-both-companies">Amazon Has 20,000 Rivian Electric Delivery Vans In Fleet: Here&#8217;s What Could Be Next For Both Companies</a></strong></li>
</ul>
<p><em>Photo by MargJohnsonVA via Shutterstock</em></p>


Government

streetTRACKS Dow Jones U.S. Large Cap Value Index Fund

iShares Dow Jones US Pharmaceuticals Index Fund

iShares Dow Jones US Health Care Provides Index Fund

iShares Trust Dow Jones US Healthcare Sector Index Fund

Your Healthcare Costs are Soaring! US Spending Reached $5 Trillion In 2023 with Major Increase in Obesity and Diabetes Drugs, Hospital Services

<p>Whales with a lot of money to spend have taken a noticeably bearish stance on <strong>Upstart Hldgs</strong>.</p>
<p>Looking at options history for Upstart Hldgs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/UPST#NASDAQ">UPST</a>) we detected 56 trades.</p>
<p>If we consider the specifics of each trade, it is accurate to state that 37% of the investors opened trades with bullish expectations and 42% with bearish.</p>
<p>From the overall spotted trades, 11 are puts, for a total amount of $386,250 and 45, calls, for a total amount of $4,604,770.</p>
<h3>What's The Price Target?</h3>
<p>Analyzing the Volume and Open Interest in these contracts, it seems that the big players have been eyeing a price window from $20.0 to $125.0 for Upstart Hldgs during the past quarter. </p>
<h3>Insights into Volume &amp; Open Interest</h3>
<p>In today's trading context, the average open interest for options of Upstart Hldgs stands at 1568.8, with a total volume reaching 16,406.00. The accompanying chart delineates the progression of both call and put option volume and open interest for high-value trades in Upstart Hldgs, situated within the strike price corridor from $20.0 to $125.0, throughout the last 30 days.</p>
<h3>Upstart Hldgs Option Activity Analysis: Last 30 Days</h3>
<p><img src="https://www.benzinga.com/files/images/story/2024/1734633111_0.png" alt="Options Call Chart" /></p>
<h3>Largest Options Trades Observed:</h3>
<p>
<table>
<thead>
<tr>
<th><strong>Symbol</strong></th>
<th><strong>PUT/CALL</strong></th>
<th><strong>Trade Type</strong></th>
<th><strong>Sentiment</strong></th>
<th><strong>Exp. Date</strong></th>
<th><strong>Ask</strong></th>
<th><strong>Bid</strong></th>
<th><strong>Price</strong></th>
<th><strong>Strike Price</strong></th>
<th><strong>Total Trade Price</strong></th>
<th><strong>Open Interest</strong></th>
<th align="right"><strong>Volume</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td>UPST</td>
<td>CALL</td>
<td>SWEEP</td>
<td>NEUTRAL</td>
<td>04/17/25</td>
<td>$14.2</td>
<td>$13.75</td>
<td>$13.75</td>
<td>$80.00</td>
<td>$490.8K</td>
<td>3.2K</td>
<td align="right">417</td>
</tr>
<tr>
<td>UPST</td>
<td>CALL</td>
<td>TRADE</td>
<td>NEUTRAL</td>
<td>01/15/27</td>
<td>$31.15</td>
<td>$28.45</td>
<td>$30.0</td>
<td>$80.00</td>
<td>$300.0K</td>
<td>397</td>
<td align="right">203</td>
</tr>
<tr>
<td>UPST</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>01/16/26</td>
<td>$15.2</td>
<td>$14.8</td>
<td>$14.8</td>
<td>$125.00</td>
<td>$296.0K</td>
<td>225</td>
<td align="right">208</td>
</tr>
<tr>
<td>UPST</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>01/16/26</td>
<td>$23.0</td>
<td>$22.9</td>
<td>$23.0</td>
<td>$80.00</td>
<td>$287.5K</td>
<td>471</td>
<td align="right">125</td>
</tr>
<tr>
<td>UPST</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>01/16/26</td>
<td>$55.6</td>
<td>$53.0</td>
<td>$53.6</td>
<td>$20.00</td>
<td>$214.4K</td>
<td>4.0K</td>
<td align="right">52</td>
</tr>
</tbody>
</table>
</p>
<h3>About Upstart Hldgs</h3>
<p>Upstart Holdings Inc provides credit services. The company provides a proprietary, cloud-based, artificial intelligence lending platform. The platform aggregates consumer demand for loans and connects it to the network of Upstart AI-enabled bank partners. Upstart's platform includes personal loans, automotive retail and refinance loans, home equity lines of credit and small dollar loans.</p>
<p>Having examined the options trading patterns of Upstart Hldgs, our attention now turns directly to the company. This shift allows us to delve into its present market position and performance</p>
<h3>Upstart Hldgs's Current Market Status</h3>
<ul>
<li>With a volume of 5,260,367, the price of UPST is up 2.78% at $75.36. </li>
<li>RSI indicators hint that the underlying stock is currently neutral between overbought and oversold.</li>
<li>Next earnings are expected to be released in 54 days.</li>
</ul>
<h3>Expert Opinions on Upstart Hldgs</h3>
<p>In the last month, 3 experts released ratings on this stock with an average target price of $84.0.</p>
<p><strong>Turn $1000 into $1270 in just 20 days?</strong></p>
<p>20-year pro options trader reveals his one-line chart technique that shows when to buy and sell. Copy his trades, which have had averaged a 27% profit every 20 days. <a href="https://www.benzinga.com/premium/ideas/options-moneyline-2/?t=Moop1arja3be22op14&amp;utm_source=benzinga-insights"><strong>Click here for access</strong></a>.<br />
&#x2A; In a positive move, an analyst from Needham has upgraded their rating to Buy and adjusted the price target to $100.<br />
&#x2A; Showing optimism, an analyst from Redburn Atlantic upgrades its rating to Buy with a revised price target of $95.<br />
&#x2A; An analyst from JP Morgan downgraded its action to Underweight with a price target of $57. </p>
<p>Trading options involves greater risks but also offers the potential for higher profits. Savvy traders mitigate these risks through ongoing education, strategic trade adjustments, utilizing various indicators, and staying attuned to market dynamics. Keep up with the latest options trades for Upstart Hldgs with <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a> for real-time alerts.</p>


UPST

This Is What Whales Are Betting On Upstart Hldgs

China Sxt Pharmaceuticals (SXTC) has released an update. China SXT Pharmaceuticals, Inc. operates through contractual arrangements known as VIE Agr...

China SXT Pharmaceuticals: Operational Risks and Profit Repatriation Challenges

Enlivex Therapeutics, Nyxoah SA, China SXT Pharmaceuticals among healthcare movers

JAGX, BSGM and SXTC among mid-day movers

BTTR, ICCM and SXTC among pre-market losers

China Sxt Pharmaceuticals (SXTC) has released an update. China SXT Pharmaceuticals, Inc. has entered into a securities purchase agreement with Stre...

China SXT Pharmaceuticals Announces New Investment Deal

HOOD, OUST and CENN are among premarket gainers

<p><a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a></p>
<p>Little-known drug manufacturer <strong>Regencell Bioscience</strong> (NASDAQ:<a href="https://investorplace.com/stock-quotes/rgc-stock-quote/"><strong>RGC</strong></a>) saw its shares skyrocket on Tuesday on no apparent catalyst. However, it&rsquo;s possible that the exceptionally distinct business profile &mdash; specializing in traditional Chinese medicine (TCM) for the treatment of neurocognitive disorders &mdash; caught the attention of speculators. While TCM offers some hope for medical utility, RGC stock remains a highly speculative investment.</p>



<p>Heading into the final stretch of the Tuesday session, Regencell gained about 345% of equity value. Naturally, the fervor over RGC stock caused the <strong>Nasdaq</strong> to <a href="https://www.nasdaqtrader.com/trader.aspx?id=TradeHalts">halt trading multiple times</a> today. As of this writing, the number of forcible halts amounted to 20 occurrences.</p>



<p>No news item appears to be responsible for the sentiment boost. Per Fintel, the <a href="https://fintel.io/ss/us/rgc">short interest</a> sits at only 0.06% of the float, with the short interest ratio coming in at only 1.64 days to cover. It&rsquo;s unlikely, then, that short-squeeze speculation sparked the lift in RGC stock. Therefore, it&rsquo;s possible that interest in Regencell&rsquo;s almost-unique business catalyzed the jump higher.</p>



<p>While the <a href="https://www.mountsinai.org/health-library/treatment/traditional-chinese-medicine#:~:text=The%20first%20writings%20about%20TCM,stayed%20in%20Asia%20for%20centuries.">first documented practice of TCM</a> dates back to 200 BCE, it&rsquo;s rare to find publicly traded companies that specialize in the field. Aside from RGC stock, <strong>China SXT Pharmaceuticals</strong> (NASDAQ:<a href="https://investorplace.com/stock-quotes/sxtc-stock-quote/"><strong>SXTC</strong></a>) is one of a small handful of enterprises that <a href="https://www.sec.gov/Archives/edgar/data/1723980/000114420418052197/tv503963_424b4.htm#:~:text=We%20are%20an%20innovative%20pharmaceutical,to%20be%20ready%20for%20use.">offer TCM products</a>.</p>



<h2>RGC Stock Enjoys Some Rational Basis for Optimism</h2>



<p>To underscore the wildness of RGC stock, it&rsquo;s barely profitable over the past 52 weeks. That goes to show prospective investors the magnitude of red ink that long-term stakeholders have suffered. Still, it would also be unfair to declare that Regencell and the underlying TCM practice is completely speculative.</p>



<p>For one thing, TCM has a long history of use. That&rsquo;s not to say that the practice doesn&rsquo;t generate side effects because <a href="https://www.hopkinsmedicine.org/health/wellness-and-prevention/chinese-medicine">adverse reactions have been noted</a>. However, some patients may feel more comfortable with the natural fundamentals of traditional solutions.</p>



<p>In addition, preliminary research into TCM shows that such therapeutics can spark positive changes in brainwave activity, thus <a href="https://www.sciencedirect.com/science/article/pii/S2667142522000884">improving behavioral challenges</a> such as hyperactivity, impulsivity and learning difficulties in subjects affected by attention deficit hyperactivity disorder (ADHD). Such research is aligned with Regencell&rsquo;s core focus, which <a href="https://finance.yahoo.com/quote/RGC/profile/">targets ADHD and autism spectrum disorder</a>.</p>



<p>Further, the TCM market is a growing one. According to Persistence Market Research, global revenue generated by the sector <a href="https://www.persistencemarketresearch.com/market-research/traditional-chinese-medicine-market.asp#:~:text=The%20Global%20revenue%20from%20the,by%20the%20end%20of%202033.">landed at $28.7 billion in 2022</a>. By 2033, the ecosystem could be worth $49.6 billion, implying a compound annual growth rate of 5.1%.</p>



<p>Still, it should be noted that TCM lacks rigorous standardized research and testing. Therefore, investors should approach RGC stock with extreme caution.</p>



<p><em><strong>On Penny Stocks and Low-Volume Stocks:</strong>&#8239;With only the rarest exceptions, InvestorPlace does not publish commentary about companies that have a market cap of less than $100 million or trade less than 100,000 shares each day. That&rsquo;s because these &ldquo;penny stocks&rdquo; are frequently the playground for scam artists and market manipulators. If we ever do publish commentary on a low-volume stock that may be affected by our commentary, we demand that&#8239;InvestorPlace.com&rsquo;s writers disclose this fact and warn readers of the risks.</em></p>



<p><em><strong>Read More:</strong>&#8239;Penny Stocks &mdash;&nbsp;</em><a href="https://investorplace.com/2014/05/fraud-penny-stocks-scams/" target="_blank"><em>How to Profit Without Getting Scammed</em></a></p>



<p><em>On the date of publication, Josh Enomoto did not have (either directly or indirectly) any positions in the securities mentioned in this article.&nbsp;The opinions expressed in this article are those of the writer, subject to the InvestorPlace.com&nbsp;</em><a href="https://investorplace.com/corporate/investorplace-publishing-guidelines/" target="_blank"><em>Publishing Guidelines</em></a><em>.</em></p>



<p><em>On the date of publication, the responsible editor did not have (either directly or indirectly) any positions in the securities mentioned in this article.</em></p>
<div><p>A former senior business analyst for Sony Electronics, Josh Enomoto has helped broker major contracts with Fortune Global 500 companies. Over the past several years, he has delivered unique, critical insights for the investment markets, as well as various other industries including legal, construction management, and healthcare. Tweet him at @EnomotoMedia.</p></div><h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2024/04/legendary-investor-predicts-forget-a-i-this-technology-is-the-future/?cid=MKT794457&amp;eid=MKT802109">Legendary Investor Predicts: &ldquo;Forget AI... THIS Technology Is the Future&rdquo;</a>
					</li>
									</ul><p>The post <a href="https://investorplace.com/2024/07/what-is-going-on-with-regencell-bioscience-rgc-stock-today/">What Is Going on With Regencell Bioscience (RGC) Stock Today?</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.</p>

What Is Going on With Regencell Bioscience (RGC) Stock Today?

China SXT Pharmaceuticals receives noncompliance notification from Nasdaq

China SXT Pharmaceuticals files for $120M mixed securities shelf

16:52 EDT China SXT Pharmaceuticals (SXTC) files $120M mixed securities shelf Published first on TheFly – the ultimate source for real-time, market...

China SXT Pharmaceuticals files $120M mixed securities shelf

ADSK

ASML

AUUD

BSGM

BTTR

CTNT

CZOO

ELVN

ENLV

FWBI

HGAS

HOOD

HUBC

ICCM

INDO

INSP

ITCI

JAGX

JBHT

KAVL

LGVN

MCBC

MDJH

NYXH

OUST

PACB

PALI

PRSO

PRZO

RVYL

RYDE

SAGE

SKIL

SYTA

URBN

WETH

WISA

YYAI

Press Releases

Thinking about buying stock in Macy's, Fisker, Verizon, Terawulf, or China SXT Pharmaceuticals?

China SXT Pharmaceuticals, Inc. Received Nasdaq Notification Letter Regarding Bid Price Deficiency

WULF

Comments

China SXT Pharmaceuticals

China SXT Pharmaceuticals (SXTC) Options

No option chain data available. Please try again later

Popular Channels

Tools & Features

Partners & Contributors

About Benzinga